No Data
No Data
Scotiabank Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13
Scotiabank analyst George Farmer maintains $Absci Corp(ABSI.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 59.8% and a
Express News | Watching Absci; Traders Circulate Banyan Hill Newsletter Has Mentioned The Stock As A Buy
Absci Is Maintained at Overweight by Keybanc
Absci Is Maintained at Overweight by
Absci Price Target Cut to $6.00/Share From $8.00 by Keybanc
Absci Price Target Cut to $6.00/Share From $8.00 by
KeyBanc Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $6
KeyBanc analyst Scott Schoenhaus maintains $Absci Corp(ABSI.US)$ with a buy rating, and adjusts the target price from $5 to $6.According to TipRanks data, the analyst has a success rate of 31.9% and
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report
No Data